Fremont, CA – October 16, 2009 As one of the world’s largest providers of ?-amyloid peptides and Alzheimer’s related research products, AnaSpec has announced its latest offering – the human recombinant ?-secretase enzyme.
Secretase (BACE1) is a key protease involved in the production of ?-amyloid peptides found in extracellular amyloid plaques of patients with Alzheimer’s disease (AD).1 This enzyme has been implicated as an important target for anti-amyloid therapy of AD.2
The recombinant human BACE1 contains the catalytic domain and a C-terminal His tag. The protein was expressed as inclusion bodies in E. coli. It was refolded and purified using ion exchange and IMAC chromatography.3 Enzyme activity can been measured in fluorescence resonance energy transfer (FRET) substrate based assays (e.g. SensoLyte® 520 Secretase Assay Kit, cat# 71144). 100 ng of ?-secretase is sufficient for this FRET-based assay.
AnaSpec’s SensoLyte™ 520 ?-Secretase Assay Kit (cat# 71144) is the industry’s only long wavelength assay kit in the green range. This kit is a fluorimetric assay kit and is sensitive, robust and easy-to-use. It employs a FRET peptide (mentioned above), facilitating high throughput screening of ?-secretase targeting drug candidates. The sequence of this FRET peptide is derived from the ?-secretase cleavage site of beta-amyloid precursor protein (APP) with Swedish mutation. This mutation enhances the susceptibility of APP to ?-secretase and results in an early onset of AD.
References:
1. Willem, M. et al. Semin Cell Dev Biol. 20,175 (2009).
2. Ghosh, K. et al. Neurotherapeutics 5, 399 (2008).
3. Tomasselli, G. et al. Protein & Peptide Letters. 15,131 (2008).
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
For more information visit www.anaspec.com
